Peptides as a therapeutic modality attract much attention due to their synthetic accessibility,
high degree of specific binding, and the ability to target protein surfaces traditionally …

Transcription factors are involved in a large number of human diseases such as cancers for
which they account for about 20% of all oncogenes identified so far. For long time, with the …

Drug discovery has traditionally focused on using libraries of small molecules to identify
therapeutic drugs, but new modalities, especially libraries of genetically encoded cyclic …

To date, small molecules and macromolecules, including antibodies, have been the most
pursued substances in drug screening and development efforts. Despite numerous …

B-cell lymphoma 6 (BCL6) is a transcriptional repressor that regulates the differentiation of B
lymphocytes and mediates the formation of germinal centers (GCs) by recruiting …

Backbone macrocyclic structures are often found in diverse bioactive peptides and
contribute to greater conformational rigidity, peptidase resistance, and potential membrane …

B-cell lymphoma 6 (BCL6) is a master regulator of germinal center formation that produce
antibody-secreting plasma cells and memory B-cells for sustained immune responses. The …

B-cell lymphoma 6 (BCL6) is a zinc finger transcriptional repressor possessing a BTB–POZ
(BR-C, ttk, and bab for BTB; pox virus and zinc finger for POZ) domain, which is required for …

Cyclic peptides discovered by genetically encoded library technologies have emerged as a
class of promising molecules in chemical biology and drug discovery. Here we review the …

With the increasing utilization of high-throughput screening for lead identification in drug
discovery, the need for easily constructed and diverse libraries which cover significant …